Emerging Biomarkers for Diagnosing Autoimmune Diseases
DOI:
https://doi.org/10.63278/10.63278/mme.v31.1Keywords:
Autoimmune diseases, biomarkers, diagnosis, immunology, molecular biology, serum biomarkers.Abstract
Autoimmune diseases represent a complex group of disorders characterized by an aberrant immune response, leading to tissue damage and dysfunction. Traditional diagnostic methods often rely on clinical symptoms and a limited panel of serological tests, which may not capture the full spectrum of the disease, particularly in early stages. Recent advances in the field of immunology and molecular biology have paved the way for the discovery of emerging biomarkers, which hold the potential to enhance diagnostic accuracy and facilitate early intervention. By investigating a range of biological samples, including blood, saliva, and tissue biopsies, researchers are uncovering novel protein signatures, genetic polymorphisms, and autoantibodies that may serve as reliable indicators of autoimmune conditions. The integration of emerging biomarkers into clinical practice could transform the diagnostic landscape for autoimmune diseases, allowing for more personalized treatment strategies. Current research focuses on specific biomarkers associated with common autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis. This study aims to synthesize existing literature and experimental findings on potential biomarkers, assess their sensitivity and specificity, and evaluate their role in distinguishing between different autoimmune conditions. By highlighting the most promising avenues for biomarker research, this study contribute to the development of targeted diagnostic tools that can improve patient outcomes and facilitate a more nuanced understanding of autoimmune disease mechanisms.
References
Autoimmune encephalitis with psychiatric features in adults: historical evolution and prospective challenge. Hansen N, Timäus C. J Neural Transm (Vienna) 2021;128:1–14. doi: 10.1007/s00702-020-02258-z.
Searching for autoimmune encephalitis: beware of normal CSF. Hébert J, Gros P, Lapointe S, et al. J Neuroimmunol. 2020;345:577285. doi: 10.1016/j.jneuroim.2020.577285.
A clinical approach to diagnosis of autoimmune encephalitis. Graus F, Titulaer MJ, Balu R, et al. Lancet Neurol. 2016;15:391–404. doi: 10.1016/S1474-4422(15)00401-9.
Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. Abboud H, Probasco JC, Irani S, et al. J Neurol Neurosurg Psychiatry. 2021;92:757–768. doi: 10.1136/jnnp-2020-325300.
Psychiatric manifestations of autoimmune encephalitis. Ford H, Griffith S, Warren N, et al. Autoimmun Rev. 2022;21:103145. doi: 10.1016/j.autrev.2022.103145.
Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lai M, Huijbers MG, Lancaster E, et al. Lancet Neurol. 2010;9:776–785. doi: 10.1016/S1474-4422(10)70137-X.
Autoimmune encephalitis: presentation, diagnosis, and management. Lancaster E. J Clin Neurol. 2022;18:373–390. doi: 10.3988/jcn.2022.18.4.373.
Autoimmune encephalitis misdiagnosis in adults. Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, et al. JAMA Neurol. 2023;80:30–39. doi: 10.1001/jamaneurol.2022.4251.
Seronegative autoimmune encephalitis: exploring the unknown. van Steenhoven RW, Titulaer MJ. Brain. 2022;145:3339–3340. doi: 10.1093/brain/awac338.
Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Irani SR, Michell AW, Lang B, et al. Ann Neurol. 2011;69:892–900. doi: 10.1002/ana.22307.
Mimickers of autoimmune encephalitis: a literature review. Alshutaihi MS, Mazketly M, Tabbakh M, Akkash N, Bahro T, Alsaman MZ. J Int Med Res. 2024;52:3000605241248050. doi: 10.1177/03000605241248050.
Management of suspected viral encephalitis in adults--Association of British Neurologists and British Infection Association National Guidelines. Solomon T, Michael BD, Smith PE, et al. J Infect. 2012;64:347–373. doi: 10.1016/j.jinf.2011.11.014.
Anti-N-methyl-D-aspartate receptor encephalitis: a severe, potentially reversible autoimmune encephalitis. Liu CY, Zhu J, Zheng XY, Ma C, Wang X. Mediators Inflamm. 2017;2017:6361479. doi: 10.1155/2017/6361479.
Autoantibodies detection in anti-N-methyl-D-aspartate receptor encephalitis. Li J, Wang Q, Wang H. Ann Transl Med. 2023;11:284. doi: 10.21037/atm-20-2279.
Clinical and MRI differential analysis of autoimmune encephalitis and viral encephalitis. Tan Y, Liu M, He L. J Taibah Univ Med Sci. 2023;18:271–278. doi: 10.1016/j.jtumed.2022.09.016.
Early-stage contactin-associated protein-like 2 limbic encephalitis: clues for diagnosis. Benoit J, Muñiz-Castrillo S, Vogrig A, et al. Neurol Neuroimmunol Neuroinflamm. 2023;10 doi: 10.1212/NXI.0000000000200041.
Anti-IgLON5 disease: a novel topic beyond neuroimmunology. Zhang YH, Ni Y, Gao YN, et al. Neural Regen Res. 2023;18:1017–1022. doi: 10.4103/1673-5374.355742.
Brain perfusion SPECT with 99mTc-HMPAO in the diagnosis and follow-up of patients with anti-NMDA receptor encephalitis. Suárez JP, Domínguez ML, Gómez MA, Portilla JC, Gómez M, Casado I. Neurologia. 2018;33:622–623. doi: 10.1016/j.nrl.2016.05.019.
The clinical spectrum of Caspr2 antibody-associated disease. van Sonderen A, Ariño H, Petit-Pedrol M, et al. Neurology. 2016;87:521–528. doi: 10.1212/WNL.0000000000002917.
LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures. Aurangzeb S, Symmonds M, Knight RK, Kennett R, Wehner T, Irani SR. Seizure. 2017;50:14–17. doi: 10.1016/j.seizure.2017.05.017.
Neuropsychiatric disorders due to limbic encephalitis: immunologic aspect. Kao YC, Lin MI, Weng WC, Lee WT. Int J Mol Sci. 2020;22 doi: 10.3390/ijms22010389.
Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Lancet Neurol. 2014;13:167–177. doi: 10.1016/S1474-4422(13)70282-5.
Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Boronat A, Gelfand JM, Gresa-Arribas N, et al. Ann Neurol. 2013;73:120–128. doi: 10.1002/ana.23756.
Expanding the clinical spectrum of anti-DPPX encephalitis: a multicenter retrospective study. Gao Y, Zhang Y, Chunyu H, et al. Front Neurosci. 2024;18:1379933. doi: 10.3389/fnins.2024.1379933.
DPPX antibody-mediated autoimmune encephalitis: the first case with breast cancer and review of the literature. Dai Y, Zheng Y, Zhu J, Ding J, Qiu K, Tang B. Heliyon. 2024;10:0. doi: 10.1016/j.heliyon.2024.e27413.
Complement in neurological disorders and emerging complement-targeted therapeutics. Dalakas MC, Alexopoulos H, Spaeth PJ. Nat Rev Neurol. 2020;16:601–617. doi: 10.1038/s41582-020-0400-0.
Role of 18F-FDG-PET imaging in the diagnosis of autoimmune encephalitis. Morbelli S, Djekidel M, Hesse S, Pagani M, Barthel H. Lancet Neurol. 2016;15:1009–1010. doi: 10.1016/S1474-4422(16)30140-5.
Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Höftberger R, Titulaer MJ, Sabater L, et al. Neurology. 2013;81:1500–1506. doi: 10.1212/WNL.0b013e3182a9585f.
Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Höftberger R, van Sonderen A, Leypoldt F, et al. Neurology. 2015;84:2403–2412. doi: 10.1212/WNL.0000000000001682.
Clinical characteristics of anti-GABA-B receptor encephalitis. Zhu F, Shan W, Lv R, Li Z, Wang Q. Front Neurol. 2020;11:403. doi: 10.3389/fneur.2020.00403.
Anti-IgLON5 disease - the current state of knowledge and further perspectives. Madetko N, Marzec W, Kowalska A, Przewodowska D, Alster P, Koziorowski D. Front Immunol. 2022;13:852215. doi: 10.3389/fimmu.2022.852215.
Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. Probasco JC, Solnes L, Nalluri A, et al. Neurol Neuroimmunol Neuroinflamm. 2017;4:0. doi: 10.1212/NXI.0000000000000352.
The essential role of neuroimaging in diagnosing and managing cerebrovascular disease in Africa: a review. Aderinto N, Olatunji D, Abdulbasit M, Edun M. Ann Med. 2023;55:2251490. doi: 10.1080/07853890.2023.2251490.
Autoimmune encephalitis [Internet] Treasure Island (FL): StatPearls Publishing; 2024. Gole S, Anand A.
Cerebrospinal fluid findings in patients with autoimmune encephalitis—a systematic analysis. Blinder T, Lewerenz J. Front Neurol. 2019;10:804. doi: 10.3389/fneur.2019.00804.
Cerebrospinal fluid (CSF) analysis and interpretation in neurocritical care for acute neurological conditions. Hrishi AP, Sethuraman M. Indian J Crit Care Med. 2019;23:0–9. doi: 10.5005/jp-journals-10071-23187.
Anti-NMDA receptor autoimmune encephalitis: diagnosis and management strategies. Nguyen L, Wang C. Int J Gen Med. 2023;16:7–21. doi: 10.2147/IJGM.S397429.
Diffusion kurtosis imaging and diffusion tensor imaging parameters applied to white matter and gray matter of patients with anti-N-methyl-D-aspartate receptor encephalitis. Liu H, Xiang Y, Liu J, et al. Front Neurosci. 2022;16:1030230. doi: 10.3389/fnins.2022.1030230.
Disturbance of gut bacteria and metabolites are associated with disease severity and predict outcome of NMDAR encephalitis: a prospective case-control study. Gong X, Liu Y, Liu X, Li A, Guo K, Zhou D, Hong Z. Front Immunol. 2021;12:791780. doi: 10.3389/fimmu.2021.791780.
Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis. Mariotto S, Gajofatto A, Zuliani L, et al. J Neurol. 2019;266:1643–1648. doi: 10.1007/s00415-019-09306-z.
Elevated CHI3L1 and OPN levels in patients with anti-N-methyl-d-aspartate receptor encephalitis. Zhao J, Wang C, Zhang Y, Sun R, Wang H, Li G, Zhang J. J Neuroimmunol. 2019;334:577005. doi: 10.1016/j.jneuroim.2019.577005.
White matter microstructural alterations in patients with anti-N-methyl-D-aspartate receptor encephalitis: a tract-based spatial statistics study. Wang X, Yin Y, Wang X, Xu G, Tian J, Ma X. Mult Scler Relat Disord. 2024;84:105500. doi: 10.1016/j.msard.2024.105500.
Typical metabolic pattern of (18)F-FDG PET in Anti-NMDAR encephalitis in the acute and subacute phases and its correlation with T2 FLAIR-MRI features. Yuan L, Mao G, Zhang Y, et al. BMC Neurosci. 2023;24:51. doi: 10.1186/s12868-023-00823-2.
Longitudinal measurement of cerebrospinal fluid neurofilament light in anti-N-methyl-D-aspartate receptor encephalitis. Macher S, Zrzavy T, Höftberger R, et al. Eur J Neurol. 2021;28:1401–1405. doi: 10.1111/ene.14631.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Mohammed Salah Hussein, Tamem Masnad Almasnad, Osama Humaidi Alshamari, Areej Mohammed Ibrahim, Alharthi, Nawaf Hamed S, Othman Omar Amodi, Yara Hisham Alkowaileet, Rahaf Abdullah Alruqi, Meaad Abdullah Alshehri, Shikhah Mohammed Alzayed, Mazen Hamad Almakrami
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their published articles online (e.g., in institutional repositories or on their website, social networks like ResearchGate or Academia), as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Except where otherwise noted, the content on this site is licensed under a Creative Commons Attribution 4.0 International License.
According to the 